Results 221 to 230 of about 124,738 (260)

Quinolinehydrazones as inhibitors of retroviral reverse transcriptase.

Farmaco (Societa chimica italiana : 1989), 1992
The inhibitory activity of a series of 2- and 4-quinolinehydrazones on retroviral reverse transcriptase has been studied on enzymes from M-MuLV, RAV-2, and on a crude lysate of HIV-1, assuming the first two enzymes as potential models of the third. The highest activity is mainly found in lipophilic, water soluble 4-quinolinehydrazones.
C. Bartolucci, L. Cellai, DI FILIPPO, PATRIZIA, V. Brizzi, C. Pellerano, L. Savini, A. Benedetto, G. Elia   +7 more
openaire   +2 more sources

Affinity of reverse transcriptase for some polynucleotide inhibitors

Archives of Biochemistry and Biophysics, 1984
The relative affinity of avian myeloblastosis virus reverse transcriptase for (U)n and a series of (U)n analogs has been measured directly in solution under conditions previously used to demonstrate the inhibitory properties of these polynucleotides.
P E, Warwick-Koochaki, A M, Bobst
openaire   +2 more sources

The Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors in the Treatment of HIV Infections (AIDS)

2013
The majority of the drugs currently used for the treatment of HIV infections (AIDS) belong to either of the following three classes: nucleoside reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs).
openaire   +2 more sources

Pharmacokinetics of Reverse Transcriptase Inhibitors

2007
The nucleoside reverse transcriptase inhibitors (NRTIs) were the first class of compounds discovered to be potent inhibitors of HIV replication (1 and, to date, these drugs remain the backbone of antiretroviral therapy. NRTIs are essentially prodrugs, inactive in their parent form and requiring activation to exert their antiviral effects (2, 3).
Patrick Hoggard, Stephen Kewn, Saye Khoo, David Back   +3 more
openaire   +1 more source

Emtricitabine: A novel nucleoside reverse transcriptase inhibitor

Drugs of Today, 2005
Emtricitabine is a once-daily nucleoside reverse transcriptase inhibitor (NRTI) that selectively and potently inhibits human immunodeficiency virus type 1 (HIV-1) replication. Emtricitabine is used in combination with other antiviral agents for the treatment of HIV-1 and is currently under investigation for the treatment of hepatitis B virus (HBV ...
Jean-Michel, Molina, Sandra L, Cox
openaire   +2 more sources

Novel HIV-1 reverse transcriptase inhibitors

Virus Research, 2008
HIV-1 reverse transcriptase (RT) was the first viral enzyme to be targeted by anti-HIV drugs. Despite 20 years of experience with RT inhibitors, new ways to inhibit this target and address viral resistance continue to emerge. In both licensed RT inhibitor classes, nucleosides (NRTIs) and non-nucleosides (NNRTIs), compounds with better resistance ...
openaire   +2 more sources

Mechanisms of genotoxicity of nucleoside reverse transcriptase inhibitors

Environmental and Molecular Mutagenesis, 2007
AbstractNucleoside analogs were first approved by the U.S. Food and Drug Administration for use against HIV‐AIDS in 1987. Since then, these agents, now commonly referred to as nucleoside reverse transcriptase inhibitors (NRTIs), have become essential components of the Highly Active Antiretroviral Therapy (HAART) drug combinations used for treatment of ...
openaire   +2 more sources

[Reverse transcriptase inhibitors, protease inhibitors].

Nihon rinsho. Japanese journal of clinical medicine, 2012
These are six different classes of antiretroviral drugs that are nucleoside/nucleotide reverse transcriptase inhibitors(NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors, CCR5 inhibitors and integrase inhibitors. NRTIs are thought as backbone of HAART(highly active antiretroviral therapy) and
openaire   +1 more source

Use of nonnucleoside reverse-transcriptase inhibitors

American Journal of Health-System Pharmacy, 1998
C D, Holtzer, R L, Coleman
openaire   +2 more sources

Nucleoside reverse transcriptase inhibitors/nucleotide reverse transcriptase inhibitors

Reactions Weekly, 2019
openaire   +1 more source